SCHEDULE 13D/A 0001954863 XXXXXXXX LIVE 17 Ordinary Shares, $0.0001 par value 10/28/2025 false 0001769484 G1117K114 Bioceres Crop Solutions Corp.

OCAMPO 210 BIS, ROSARIO C1 2000

Gloria Montaron Estrada 54 0341 4861100 Bioceres Group Limited Highdown House, Yeoman Way, Worthing West Sussex X0 BN99 3HH 0001954863 N Bioceres Group Limited a N X0 44161.00 6221079.00 44161.00 3145000.00 6265240.00 N 10 HC (1) Bioceres Group Limited may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC as Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group Limited. (2) Includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1. Y Bioceres LLC a N DE 0.00 6221079.00 0.00 3145000.00 6221079.00 N 9.9 HC (1) Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group Limited. As a result, Bioceres Group Limited may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC (2) Includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1. Ordinary Shares, $0.0001 par value Bioceres Crop Solutions Corp. OCAMPO 210 BIS, ROSARIO C1 2000 EXPLANATORY NOTE This Amendment No. 17 (the "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 14, 2019, (as amended by Amendment No. 1 filed with the SEC on July 2, 2020, Amendment No. 2 filed with the SEC on August 28, 2020, Amendment No. 3 filed with the SEC on November 25, 2020, Amendment No. 4 filed with the SEC on August 6, 2021, Amendment No. 5 filed with the SEC on October 15, 2021, Amendment No. 6 filed with the SEC on April 5, 2022, Amendment No. 7 filed with the SEC on July 25 2022, Amendment No. 8 filed with the SEC on November 15, 2022, Amendment No. 9 filed with the SEC on March 25, 2024, Amendment No. 10 filed with the SEC on September 20, 2024, Amendment No. 11 filed with the SEC on January 6, 2025, Amendment No. 12 filed with the SEC on March 26, 2025, Amendment No. 13 filed with the SEC on June 6, 2025, Amendment No. 14 filed with SEC on July 9, 2025, and Amendment No. 15 filed with SEC on August 7, 2025, and Amendment No. 16 filed with SEC on September 17, 2025 (the "Schedule 13D"), by Bioceres Group Limited and Bioceres LLC (each a "Reporting Person", and herein collectively referred as the "Reporting Persons"). This Amendment is being filed to report a decrease in the Shares beneficially owned by the Reporting Persons as a result of the settlement of certain financial obligations through payment-in-kind made in Shares relating to private transactions (the "Transaction"). As a result of the foregoing, the Shares owned by the Reporting Persons decreased from 9,432,896 to 3,189,161. The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as expressly amended and supplemented by this Amendment, the Schedule 13D is not amended or supplemented in any respect. Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D. The aggregate percentages of Shares beneficially owned by the Reporting Persons, and reported in this Amendment, is calculated based on 62,848,483 Shares outstanding, as reported by the Issuer in its annual report on Form 20-F filed with the SEC on October 30, 2024 (File No. 001-38836) (the "Issuer 20-F"). i) Bioceres Group Limited, which is the holder of record of 44,161 Shares (corresponding to approximately 0.07% of the Issuer's outstanding capital stock) and through its subsidiary Bioceres LLC, holds an additional 3,145,000 Shares (corresponding to approximately 5.07% of the Issuer's outstanding capital stock); and ii) Bioceres LLC, which is the holder of record of 3,145,000 Shares (corresponding to approximately 5% of the Issuer's outstanding capital stock). All disclosures herein with respect to any Reporting Person are made only by such Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. i) Bioceres Group Limited is Highdown House, Yeoman Way, Worthing, West Sussex, United Kingdom, BN99 3HH; and ii) Bioceres LLC is 1209 Orange Street, Wilmington 19801-1120, County of New Castle Not applicable. None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. i) Bioceres Group Limited is a company organized under the laws of England and Wales; and ii) Bioceres LLC is limited liability company formed under the laws of Delaware Please refer to the "Explanatory Note" of this Amendment. The purpose of the Transaction was to fund the payment of financial obligations which were due. As a result of the Transaction, the Shares owned by the Reporting Persons, which are not subject to the shareholders' agreement described under Item 6 of the Schedule 13D, decreased from 9,432,896 Shares to 3,189,161 Shares. In addition, 3,076,079 Shares which the Reporting Persons have the shared power to vote or to direct the vote of are subject to the shareholders' agreement described under Item 6 of the Schedule 13D. As a result of the foregoing, in the aggregate, the Reporting Persons beneficially own 6,265,240 Shares (corresponding to approximately 10% of the Issuer's outstanding capital stock). Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D. Bioceres Group Limited a) Amount beneficially owned: 6,265,240 Percentage: 10% Bioceres LLC a) Amount beneficially owned: 6,221,079 Percentage: 9.9% Bioceres Group Limited b) Number of shares to which the Reporting Person has: i. Sole power to vote or to direct the vote: 44,161 ii. Shared power to vote or to direct the vote: 6,221,079 iii. Sole power to dispose or to direct the disposition of: 44,161 iv. Shared power to dispose or to direct the disposition of: 3,145,000 Bioceres LLC b) Number of shares to which the Reporting Person has: i. Sole power to vote or to direct the vote: -- ii. Shared power to vote or to direct the vote: 6,221,079 iii. Sole power to dispose or to direct the disposition of: -- iv. Shared power to dispose or to direct the disposition of: 3,145,000 None of the Reporting Persons has effected any transactions of the Issuer's Shares during the 60 days preceding the date of this report, except as described in Item 4 of this Schedule 13D/A which information is incorporated herein by reference. Not applicable. Not applicable. Exhibit 10.1* Shareholders Agreement, dated as of March 5, 2019, by and among Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. Exhibit 99.1* Joint Filing Agreement dated March 25, 2024, by and among the Reporting Persons. * Previously filed. Bioceres Group Limited /s/ Gloria Montaron Estrada 10/28/2025 Bioceres LLC /s/ Gloria Montaron Estrada 10/28/2025